Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on February 17, 2019, and February 21, 2019, with the report filed on February 22, 2019. Exicure, Inc., an emerging growth company, reported the entry into a material definitive agreement and the finalization of a separation agreement with a former executive.
Key Financial Metrics and Agreements
The filing details a License and Development Agreement with Dermelix, LLC d/b/a Dermelix Biotherapeutics. Key financial terms include:
- Upfront Payment: Dermelix is obligated to pay an advance of $1 million within ten business days, applied against initial development expenses.
- Option Exercise Fees: Dermelix may exercise options for up to five additional orphan diseases, paying $1 million per option, applied against development expenses.
- Milestone Payments: Exicure is eligible for up to $13.5 million in development and regulatory milestones and up to $152.5 million in sales milestones per licensed product.
- Royalties: The Company will receive low double-digit royalties on annual net sales.
- Severance: The separation agreement with former Chief Scientific Officer Ekambar Kandimalla, Ph.D., provides for severance totaling six months of base salary.
The filing does not provide current revenue, profit, cash flow, or debt figures as this is a current report regarding specific events rather than a periodic financial statement.
Material Changes and Operational Updates
Strategic Partnership: Exicure granted Dermelix an exclusive, worldwide royalty-bearing license to develop and commercialize Exicure's spherical nucleic acid (SNA) technology for Netherton Syndrome (NS) and up to five additional dermatology orphan diseases. Exicure will conduct early-stage development up to IND-enabling toxicology studies, while Dermelix assumes subsequent development, commercialization, and financial responsibility.
Executive Departure: Dr. Ekambar Kandimalla resigned as Chief Scientific Officer effective February 1, 2019. A separation agreement became irrevocable on February 21, 2019, extending the exercise period for his vested options to 24 months post-separation.
Outlook, Risks, and Contingencies
Termination Rights: Dermelix may terminate the agreement in its sole discretion with prior written notice. Upon such termination, all licenses granted to Dermelix will terminate. If Exicure terminates due to non-achievement of a development milestone, the license for that specific product converts to a fully-paid, royalty-free, perpetual license.
Change of Control: In the event of a change of control, Dermelix has 90 days to exercise remaining options; unexercised options will lapse.
Risks: The Company's future revenue from this agreement is contingent upon Dermelix exercising options, achieving development milestones, and generating sales. The filing notes that the full text of the agreements is required for complete understanding of representations, warranties, and indemnities.
Investor Verification Checklist
- Verify the receipt of the $1 million advance payment from Dermelix.
- Monitor the execution of the option rights for the five additional orphan diseases.
- Review the upcoming Form 10-Q for the full text of the License Agreement and Separation Agreement.
- Assess the impact of the Chief Scientific Officer's departure on the Company's early-stage development capabilities.
- Track the progress of IND-enabling toxicology studies for Netherton Syndrome.